Doctors in New York will soon test an experimental therapy for COVID-19 that uses blood from people who recover from the disease, according to news reports.
The therapy, known as convalescent plasma, takes advantage of the virus-fighting antibodies that are present in people's blood after they recover from the illness, according to NBC News.
For the trial, researchers would collect plasma — the liquid portion of blood that does not include blood cells or platelets — from recovered COVID-19 patients. Researchers would then harvest antibodies against the new coronavirus from the plasma, and these antibodies would then be injected into people sick with COVID-19. The study researchers will then evaluate whether convalescent plasma improves disease outcomes.
—Coronavirus in the US: Map & cases (opens in new tab)
—What are the symptoms? (opens in new tab)
—How deadly is the new coronavirus? (opens in new tab)
—How long does virus last on surfaces? (opens in new tab)
—Is there a cure for COVID-19? (opens in new tab)
—How does it compare with seasonal flu? (opens in new tab)
—How does the coronavirus spread? (opens in new tab)
—Can people spread the coronavirus after they recover? (opens in new tab)
"There have been tests that show when a person is injected with the antibodies, that then stimulates and promotes their immune system against that disease," Gov. Andrew Cuomo said at a news briefing Monday (March 23).
The trial, which officials plan to start this week, would only treat people who are seriously ill with COVID-19, Cuomo said.
This type of therapy is more than 100 years old and was used during the 1918 flu pandemic, a time when antiviral drugs and most vaccines did not exist, according to NBC News.
Recruiting for plasma donors would likely start in New Rochelle, a suburb of New York City where many of the state's initial cases occurred, according to NBC.
- The 9 deadliest viruses on Earth
- 20 of the worst epidemics and pandemics in history
- 28 Devastating Infectious Diseases
Originally published on Live Science.